210 related articles for article (PubMed ID: 22869577)
21. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
[TBL] [Abstract][Full Text] [Related]
22. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
[TBL] [Abstract][Full Text] [Related]
23. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
[TBL] [Abstract][Full Text] [Related]
24. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
[TBL] [Abstract][Full Text] [Related]
25. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Deutsch M; Papatheodoridis GV
Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
[TBL] [Abstract][Full Text] [Related]
26. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.
Kati W; Koev G; Irvin M; Beyer J; Liu Y; Krishnan P; Reisch T; Mondal R; Wagner R; Molla A; Maring C; Collins C
Antimicrob Agents Chemother; 2015 Mar; 59(3):1505-11. PubMed ID: 25534735
[TBL] [Abstract][Full Text] [Related]
28. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.
Rajagopalan R; Pan L; Schaefer C; Nicholas J; Lim S; Misialek S; Stevens S; Hooi L; Aleskovski N; Ruhrmund D; Kossen K; Huang L; Yap S; Beigelman L; Serebryany V; Liu J; Sastry S; Seiwert S; Buckman B
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795376
[TBL] [Abstract][Full Text] [Related]
30. Computational study on the drug resistance mechanism of HCV NS3 protease to BMS-605339.
Wang H; Guo C; Chen BZ; Ji M
Biotechnol Appl Biochem; 2017 Mar; 64(2):153-164. PubMed ID: 26790544
[TBL] [Abstract][Full Text] [Related]
31.
Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H
J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196
[TBL] [Abstract][Full Text] [Related]
32. Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
Ikegami T; Ueda Y; Akamatsu N; Ishiyama K; Goto R; Soyama A; Kuramitsu K; Honda M; Shinoda M; Yoshizumi T; Okajima H; Kitagawa Y; Inomata Y; Ku Y; Eguchi S; Taketomi A; Ohdan H; Kokudo N; Shimada M; Yanaga K; Furukawa H; Uemoto S; Maehara Y
Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28881052
[TBL] [Abstract][Full Text] [Related]
33. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
Akamatsu N; Sugawara Y; Kokudo N
Expert Rev Anti Infect Ther; 2015; 13(11):1307-17. PubMed ID: 26414905
[TBL] [Abstract][Full Text] [Related]
34. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
Fenaux M; Eng S; Leavitt SA; Lee YJ; Mabery EM; Tian Y; Byun D; Canales E; Clarke MO; Doerffler E; Lazerwith SE; Lew W; Liu Q; Mertzman M; Morganelli P; Xu L; Ye H; Zhang J; Matles M; Murray BP; Mwangi J; Zhang J; Hashash A; Krawczyk SH; Bidgood AM; Appleby TC; Watkins WJ
Antimicrob Agents Chemother; 2013 Feb; 57(2):804-10. PubMed ID: 23183437
[TBL] [Abstract][Full Text] [Related]
35. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
Gottwein JM; Scheel TK; Jensen TB; Ghanem L; Bukh J
Gastroenterology; 2011 Sep; 141(3):1067-79. PubMed ID: 21699793
[TBL] [Abstract][Full Text] [Related]
36. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
White PW; Llinàs-Brunet M; Amad M; Bethell RC; Bolger G; Cordingley MG; Duan J; Garneau M; Lagacé L; Thibeault D; Kukolj G
Antimicrob Agents Chemother; 2010 Nov; 54(11):4611-8. PubMed ID: 20823284
[TBL] [Abstract][Full Text] [Related]
37. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).
Lenz O; Vijgen L; Berke JM; Cummings MD; Fevery B; Peeters M; De Smedt G; Moreno C; Picchio G
J Hepatol; 2013 Mar; 58(3):445-51. PubMed ID: 23142061
[TBL] [Abstract][Full Text] [Related]
38. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Cho BW; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB
Clin Mol Hepatol; 2017 Mar; 23(1):51-56. PubMed ID: 28297836
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.
Pilot-Matias T; Tripathi R; Cohen D; Gaultier I; Dekhtyar T; Lu L; Reisch T; Irvin M; Hopkins T; Pithawalla R; Middleton T; Ng T; McDaniel K; Or YS; Menon R; Kempf D; Molla A; Collins C
Antimicrob Agents Chemother; 2015 Feb; 59(2):988-97. PubMed ID: 25451053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
